CCQO:院外心脏停搏患者生存结局得到显著改善,但仍存在区域差异

2015-01-30 MedSci MedSci原创

莫纳什大学Nehme Z等人通过对维多利亚急救心脏停搏注册表的数据研究,地域和时间跨度上分析了心肺复苏的趋势,事件生存率,出院生存率,研究成果发表在1月份Circulation Cardiovascular quality and outcomes期刊上。 背景:虽然临床登记的价值已经在发达国家得到了很好的认可,但是其用于衡量急诊医疗质量仍然比较陌生。研究提出了一个全州急诊医疗监督举

莫纳什大学Nehme Z等人通过对维多利亚急救心脏停搏注册表的数据研究,地域和时间跨度上分析了心肺复苏的趋势,事件生存率,出院生存率,研究成果发表在1月份Circulation Cardiovascular quality and outcomes期刊上。
 
背景:
虽然临床登记的价值已经在发达国家得到了很好的认可,但是其用于衡量急诊医疗质量仍然比较陌生。研究提出了一个全州急诊医疗监督举措,用来衡量院外心脏停搏患者的医疗护理系统质量。
 
方法和结果:
2002年1月1日至2012年1月30日期间,在澳大利亚东南部维多利亚州,从维多利亚急救心脏停搏注册表中,选取心源性院外心脏停搏的患者数据。从区域和时间跨度上对旁观者心肺复苏生存率,以及出院存活率进行logistic回归分析和多水平模型分析。收录32097例院外心脏停搏患者,其中14083例(占43.9%)接受了急诊医疗服务。旁观者心肺复苏后的风险调整比率(OR=2.96;95%可信区间为2.62-3.33),生存率(OR=1.55;95%可信区间1.30-1.85),出院生存率(OR=2.81;95%可信区间2.07-3.82)2011年至2012年相对于基线水平显著升高。跨区域观测旁观者心肺复苏显著变化和生存率可知,乡村地区心脏停搏患者不太可能存活至出院。存活至出院的院内变化平均OR值为1.70。
 
结局:
2002年至2012年期间,澳大利亚维多利亚州,旁观者心肺复苏院外心脏停搏患者生存结局得到显著改善。但是,区域生存差异和院内变化在未来对患者的护理中仍然是一项重大的挑战。

原始出处:

Nehme Z, Bernard S, Cameron P, Bray JE, Meredith IT, Lijovic M, Smith K. Using a cardiac arrest registry to measure the quality of emergency medical service care: decade of findings from the victorian ambulance cardiac arrest registry. Circulation Cardiovascular quality and outcomes. 2015, Jan;8(1):56-66.

本文是MedSci原创,欢迎转载,转载请注明出处,非常感谢!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1715899, encodeId=1a451e1589988, content=<a href='/topic/show?id=6e095142ee3' target=_blank style='color:#2F92EE;'>#心脏停搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51427, encryptionId=6e095142ee3, topicName=心脏停搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b91132095598, createdName=klivis, createdTime=Mon Mar 02 20:57:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932521, encodeId=0c74193252129, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun May 17 06:57:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16463, encodeId=5e9a1646324, content=提高了不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Thu Feb 19 13:03:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16214, encodeId=ed5216214a6, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:56:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15479, encodeId=82fd154e9ad, content=明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sun Feb 15 13:55:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14878, encodeId=36e9148e870, content=整体水平提升, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jan 30 19:50:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1715899, encodeId=1a451e1589988, content=<a href='/topic/show?id=6e095142ee3' target=_blank style='color:#2F92EE;'>#心脏停搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51427, encryptionId=6e095142ee3, topicName=心脏停搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b91132095598, createdName=klivis, createdTime=Mon Mar 02 20:57:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932521, encodeId=0c74193252129, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun May 17 06:57:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16463, encodeId=5e9a1646324, content=提高了不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Thu Feb 19 13:03:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16214, encodeId=ed5216214a6, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:56:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15479, encodeId=82fd154e9ad, content=明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sun Feb 15 13:55:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14878, encodeId=36e9148e870, content=整体水平提升, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jan 30 19:50:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1715899, encodeId=1a451e1589988, content=<a href='/topic/show?id=6e095142ee3' target=_blank style='color:#2F92EE;'>#心脏停搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51427, encryptionId=6e095142ee3, topicName=心脏停搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b91132095598, createdName=klivis, createdTime=Mon Mar 02 20:57:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932521, encodeId=0c74193252129, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun May 17 06:57:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16463, encodeId=5e9a1646324, content=提高了不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Thu Feb 19 13:03:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16214, encodeId=ed5216214a6, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:56:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15479, encodeId=82fd154e9ad, content=明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sun Feb 15 13:55:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14878, encodeId=36e9148e870, content=整体水平提升, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jan 30 19:50:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
    2015-02-19 午夜星河

    提高了不少

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1715899, encodeId=1a451e1589988, content=<a href='/topic/show?id=6e095142ee3' target=_blank style='color:#2F92EE;'>#心脏停搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51427, encryptionId=6e095142ee3, topicName=心脏停搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b91132095598, createdName=klivis, createdTime=Mon Mar 02 20:57:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932521, encodeId=0c74193252129, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun May 17 06:57:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16463, encodeId=5e9a1646324, content=提高了不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Thu Feb 19 13:03:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16214, encodeId=ed5216214a6, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:56:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15479, encodeId=82fd154e9ad, content=明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sun Feb 15 13:55:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14878, encodeId=36e9148e870, content=整体水平提升, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jan 30 19:50:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
    2015-02-17 chinayinhan

    已阅

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1715899, encodeId=1a451e1589988, content=<a href='/topic/show?id=6e095142ee3' target=_blank style='color:#2F92EE;'>#心脏停搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51427, encryptionId=6e095142ee3, topicName=心脏停搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b91132095598, createdName=klivis, createdTime=Mon Mar 02 20:57:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932521, encodeId=0c74193252129, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun May 17 06:57:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16463, encodeId=5e9a1646324, content=提高了不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Thu Feb 19 13:03:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16214, encodeId=ed5216214a6, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:56:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15479, encodeId=82fd154e9ad, content=明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sun Feb 15 13:55:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14878, encodeId=36e9148e870, content=整体水平提升, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jan 30 19:50:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
    2015-02-15 午夜星河

    明白

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1715899, encodeId=1a451e1589988, content=<a href='/topic/show?id=6e095142ee3' target=_blank style='color:#2F92EE;'>#心脏停搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51427, encryptionId=6e095142ee3, topicName=心脏停搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b91132095598, createdName=klivis, createdTime=Mon Mar 02 20:57:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932521, encodeId=0c74193252129, content=<a href='/topic/show?id=5cd95305803' target=_blank style='color:#2F92EE;'>#患者生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53058, encryptionId=5cd95305803, topicName=患者生存)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Sun May 17 06:57:00 CST 2015, time=2015-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16463, encodeId=5e9a1646324, content=提高了不少, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Thu Feb 19 13:03:00 CST 2015, time=2015-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16214, encodeId=ed5216214a6, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=da6b7222, createdName=chinayinhan, createdTime=Tue Feb 17 00:56:00 CST 2015, time=2015-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15479, encodeId=82fd154e9ad, content=明白, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200609/ef6a57dbe7f1489dad7446b7c5217858/d5e4fe65996c4446a029b0f5d056abb1.jpg, createdBy=6b011518214, createdName=午夜星河, createdTime=Sun Feb 15 13:55:00 CST 2015, time=2015-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=14878, encodeId=36e9148e870, content=整体水平提升, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Fri Jan 30 19:50:00 CST 2015, time=2015-01-30, status=1, ipAttribution=)]
    2015-01-30 lovetcm

    整体水平提升

    0

相关资讯

NEJM:心肺复苏时家属在场会产生积极影响

心肺复苏(CPR)期间患者家庭成员在场对他们本身和医疗小组有什么影响仍存在争议。法国巴黎公共救助医院(AP-HP)紧急医疗救助服务部(SAMU)的研究者对此进行了深入研究,他们发现,CPR实施过程中患者家属在场会对心理学变量的结果产生积极的影响,并且未干扰医疗投入程度、未加重医疗保健组的应激、也未导致医疗法律索赔。相关论文发表于国际权威杂志NEJM 2013年6月份在线版。 研究纳入了因心脏停搏

Anesth Analg:富氢液可提高心肺复苏后生存率

在全世界范围内,心跳骤停是引发死亡的一个主要原因。随着技术手段的不断更新,心肺复苏的成功率已经提到30%-40%。但是令人遗憾的是,这些被成功复苏的病人中约有3/4的人最终还是死亡或者遗留永久性的神经系统功能损害。 低温治疗技术在临床上已经得到了验证,可以有效的提高患者的预后。我们现在急需寻找一种药物配合低温治疗来改善心肺复苏之后的病人的预后。 富氢液是一种富含氢气的生理盐水,其特点是

心肺复苏研究的若干新进展

自2010年美国心脏学会心肺复苏(CPR)与心J&L管病急救(ECC)指南(简称国际CPR指南)修订已经三年时间,每次指南的实践和推广,都会引起新的研究热点和理论争议。随着循证医学与转化医学的不断发展与广泛应用,CPR的研究近年来也取得了一定的进展。 1.通气在心肺复苏中的作用 2010年国际CPR指南将成人和儿童(不包括新生儿)基本生命支持修订为“

NEJM:喉罩气道管理用于急诊心肺复苏安全有效

2013年11月14日,NEJM临床视频版块发表了喉罩( LMA )气道管理在心跳呼吸骤停时的使用,引起各方强烈关注。NEJM近期就上述视频发表了读者来信及作者回复,现编译如下。伯明翰阿拉巴马大学医学院的Henry博士等认为,视频反映了喉罩( LMA )气道管理应用于心跳呼吸骤停的实用性。但现有支持急诊应用该装置和其他声门上通气装置(如喉管)的数据有限,且与视频不一致。Lighthall等声明LM

JAMA:普及远程指导心肺复苏术意义重大

早在1960年,就有人提出闭式胸外按压术可以用来治疗心脏骤停,也为治疗这种头号致死性疾病提出了一个具有变革意义的理论基础。作者甚至激动的写道“任何人在任何地点都可以进行心脏复苏术操作,而手术器材就是我们的双手”。【原文下载】今天,这种急救措施已经演变成为我们所熟知的心肺复苏术(CPR)。通过CPR,心脏骤停的存活率提高了2至3倍。起初,人们认为只有临床医生才可以实施CPR,但是类似CPR的复苏术成

AHA 2014:机械与人工心肺复苏效果相当(PARAMEDIC)

美国心脏学会(AHA)2014年科学年会上公布且11月16日在线发表于Lancet的一项随机试验PARAMEDIC结果显示,在改善心脏骤停患者30天生存率方面,机械(LUCAS-2)心肺复苏相较于人工心肺复苏没有明显优势。研究内容与结果研究者将院外心脏骤停的患者随机分至LUCAS-2胸部按压组(实验组)和人工心肺复苏组(对照组),通过意向治疗分析比较两组间心脏骤停30天内的生存率。结果为,实验组纳